Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OMT for Mild-Moderate OSA
NCT06681974Phase 3Recruiting
- Sponsor
- IDIVAL
- Start
- May 2023
- Primary completion
- May 2024
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial (2 arms), sponsored by IDIVAL. Primary endpoint: Apnea-Hypopnea Index at 12 months. Started May 2023; status: recruiting.
Beyond the preview
Go deeper on NCT06681974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06681974.